Gen-Probe Tallies Record Revenues in Q4 2011 as Aptima Tests, Blood Screening Thrive | GenomeWeb

By Ben Butkus

Gen-Probe this week reported record revenues of $158.2 million in the fourth quarter of 2011, driven primarily by sales of clinical diagnostics and blood screening products.

The positive performance was primarily fueled by domestic and international growth of its Aptima Combo 2 assay for chlamydia and gonorrhea; and by increased shipments of assays and Tigris instruments to blood-screening partner Novartis, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.